United Therapeutics (UTHR) Tops Q1 EPS by 10c
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $6.63, $0.10 better than the analyst estimate of $6.53. Revenue for the quarter came in at $794.4 million versus the consensus estimate of $728.34 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
